Eiger BioPharmaceuticals (NASDAQ:EIGR) completed enrollment of the Phase 2 ULTRA study designed to evaluate the effects of ubenimex in patients with primary and secondary lymphedema of the lower limbs. A total of 54 patients were enrolled across sites in the U.S. and Australia.Read More
Roth Capital Partners initiated coverage of Eiger Biopharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $35 price target. The stock closed at $11.65 on Oct. 18.Read More
BTIG downgraded Tactile Systems Technology (NASDAQ:TCMD) to “neutral” from “buy,” saying the stock is up more than 100% year-to-date, exceeding its price target of $35. The stock closed at $36.79 on Sept. 15.Read More
BTIG initiated coverage of Eiger BioPharmaceuticals (NASDAQ:EIGR) with a “buy” rating and $32 price target. The stock closed at $7.45 on July 13.Read More
Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.
Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.Read More